Nuvo Research has enrolled the first patient in its European Phase II clinical trial evaluating the immune modulating drug candidate WF10 for the treatment of allergic rhinitis, also known as hay fever.
The trial, which will enroll 50 patients, will assess the efficacy and safety of WF10 infusions for patients with severe persistent allergic rhinitis.
Go deeper with GlobalData
Patients who meet the trial criteria will be randomised into two groups – WF10 and placebo – and treatment will be administered once daily for five consecutive days, while the assessment will spread over a three-month period.
The trial is scheduled to be complete by early 2011.
The Canadian drug development firm is co-developing WF10 with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
